Lab Seeks Federal Permission to Import Obscure Controlled Substances
Published Date: 11/12/2026
Notice
Summary
NSI Lab Solutions LLC wants to become an official importer of certain controlled substances, like Amineptine and Mesocarb. People who make or use these drugs can share their thoughts or ask for a hearing by December 14, 2026. This move could affect companies handling these substances and involves a formal review process with no immediate cost changes announced.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Company applied to import many controlled substances
NSI Lab Solutions LLC applied on September 9, 2026 to be registered to import a long list of controlled substances (examples include Amineptine and Mesocarb) for sale to customers for analytical and research purposes only. If approved, businesses that buy controlled substances for lab analysis or research could buy these imported chemicals from NSI.
Marijuana codes limited to synthetic forms
For drug code 7360 (Marihuana) and 7370 (Tetrahydrocannabinols), NSI plans to import a synthetic cannabidiol and a synthetic tetrahydrocannabinol only; no other activities for those drug codes are authorized for this registration. Customers needing natural marijuana extracts or other THC/CBD forms would not be able to obtain those from NSI under this registration.
No import of finished dosage forms allowed
The registration would not authorize NSI to import Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. That means NSI may import substances for research/analytical use but cannot import finished pharmaceutical products for sale.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22955, Troy R. Lehman, D.O.; Decision and Order
Troy R. Lehman, D.O., lost his DEA registration because he didn’t have the proper state permission and lied on his renewal forms. Since he didn’t ask for a hearing, the DEA revoked his registration by default, stopping him from handling controlled substances. This change is effective immediately and means he can no longer legally work with these drugs.
2026-22954, Traci B. Lujan, A.P.R.N.; Decision and Order
Traci B. Lujan, a nurse practitioner from Utah, lost her DEA registration because she no longer has permission to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her certificate. This means she can’t legally prescribe or manage certain medications anymore, effective immediately.
Previous / Next Documents
Previous: 2026-23004, Final Effect of the Designation of a Class of Employees for Addition to the Special Exposure Cohort
The government just added certain construction workers from the Savannah River Site (1991-1993) to a special group that helps people exposed to harmful stuff on the job. If you worked at least 250 days as a subcontractor there during that time, you’re now covered for easier health claims starting August 7, 2026. This means faster help and possible compensation for those affected—no extra cost to workers!
Next: 2026-23008, Privacy Act of 1974; System of Records
The NIH is retiring an old privacy notice for its Business System because the same info is now protected under newer, broader rules. This change affects anyone whose data is in the NIH Business System Cloud, but don’t worry—the records are still safe and managed properly. The update takes effect immediately with no extra costs involved.